SciSparc Ltd. (SPRC)
NASDAQ: SPRC · Real-Time Price · USD
0.238
+0.001 (0.42%)
At close: Nov 20, 2024, 4:00 PM
0.235
-0.003 (-1.39%)
After-hours: Nov 20, 2024, 5:30 PM EST
SciSparc Revenue
SciSparc had revenue of $840.00K in the half year ending June 30, 2024. This brings the company's revenue in the last twelve months to $1.75M, down -47.36% year-over-year. In the year 2023, SciSparc had annual revenue of $2.88M with 113.73% growth.
Revenue (ttm)
$1.75M
Revenue Growth
-47.36%
P/S Ratio
0.18
Revenue / Employee
$582,333
Employees
3
Market Cap
853.85K
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSPRC News
- 7 weeks ago - SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment - GlobeNewsWire
- 2 months ago - SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX - GlobeNewsWire
- 2 months ago - SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment - GlobeNewsWire
- 2 months ago - SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment - GlobeNewsWire
- 2 months ago - SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy - GlobeNewsWire
- 2 months ago - SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer - GlobeNewsWire
- 2 months ago - SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - GlobeNewsWire
- 2 months ago - SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination - GlobeNewsWire